RAF Mutation clinical trials at University of California Health

1 research study open to eligible people

Showing trials for

  • ABM-168 in Adults With Advanced Solid Tumors.

    open to eligible people ages 18 years and up

    This is a Phase 1, First-in-Human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ABM-168 in adult patients with RAS or RAF or NF-1 mutated advanced solid tumors as ABM-168 may have a significant effect in inhibiting cell growth.

    at UCSF

Our lead scientists for RAF Mutation research studies include .

Last updated: